TCGA-BH-A0C0-01A-21R-A056-07
— · C
Clinical attributes
From the source cohort, normalized into canonical keys plus the project's native columns.
- cancer_type
- —
- cancer_type_detailed
- —
- subtype
- C
- subtype
- C
- overall_survival_months
- 42
GSVA pathway preview (50 Hallmark scores)
Top 10 most elevated and top 10 most suppressed Hallmark pathways for this sample.
Top 10 elevated
- INTERFERON_GAMMA_RESPONSE+0.570
- ALLOGRAFT_REJECTION+0.560
- INTERFERON_ALPHA_RESPONSE+0.550
- IL6_JAK_STAT3_SIGNALING+0.470
- INFLAMMATORY_RESPONSE+0.450
- REACTIVE_OXYGEN_SPECIES_PATHWAY+0.410
- E2F_TARGETS+0.400
- G2M_CHECKPOINT+0.390
- MTORC1_SIGNALING+0.380
- MYC_TARGETS_V2+0.320
Top 10 suppressed
- EPITHELIAL_MESENCHYMAL_TRANSITION-0.460
- ANGIOGENESIS-0.430
- HEDGEHOG_SIGNALING-0.420
- TGF_BETA_SIGNALING-0.390
- UV_RESPONSE_DN-0.360
- WNT_BETA_CATENIN_SIGNALING-0.280
- NOTCH_SIGNALING-0.210
- MYOGENESIS-0.200
- APICAL_JUNCTION-0.180
- HYPOXIA-0.150
Patient twins — nearest pathway neighbors
10 samples closest to this one in 50-dim pathway space, drawn from the Pathway Atlas. Cosine similarity = 1 means identical pathway state.
10 twins match this tumor's tissue · 0 come from a different tissue of origin
| # | Sample | Cancer type | Subtype | cos similarity |
|---|---|---|---|---|
| 1 | SRR35579807 | — | C | 0.882 |
| 2 | ERR2208905 | — | — | 0.874 |
| 3 | TCGA-EW-A1PB-01A-11R-A144-07 | — | E | 0.870 |
| 4 | SRR8518156 | — | D | 0.858 |
| 5 | 992ce1bc-46a2-4f57-ac7a-c6368c69c67c | — | — | 0.857 |
| 6 | TCGA-E9-A22D-01A-11R-A157-07 | — | D | 0.852 |
| 7 | TCGA-C8-A1HM-01A-12R-A137-07 | — | C | 0.843 |
| 8 | TCGA-AR-A0U0-01A-11R-A109-07 | — | E | 0.843 |
| 9 | GSM5359439 | — | — | 0.838 |
| 10 | BSR_02_0048_A10_S104 | — | C | 0.838 |
Per-pathway drug coverage
For each elevated pathway in this tumor, the best-reversing drug across the catalog. Uncovered pathways = unmet need at pathway level for this one patient.
0 of 33 elevated pathways have at least one drug that meaningfully reverses them.
| Pathway (elevated) | tumor score | Best drug | reversal magnitude |
|---|---|---|---|
| INTERFERON_GAMMA_RESPONSE | 0.570 | Idelalisib | — uncovered |
| ALLOGRAFT_REJECTION | 0.560 | Idelalisib | — uncovered |
| INTERFERON_ALPHA_RESPONSE | 0.550 | Inavolisib | — uncovered |
| IL6_JAK_STAT3_SIGNALING | 0.470 | Inavolisib | — uncovered |
| INFLAMMATORY_RESPONSE | 0.450 | Idelalisib | — uncovered |
| REACTIVE_OXYGEN_SPECIES_PATHWAY | 0.410 | Inavolisib | — uncovered |
| E2F_TARGETS | 0.400 | Inavolisib | — uncovered |
| G2M_CHECKPOINT | 0.390 | Inavolisib | — uncovered |
| MTORC1_SIGNALING | 0.380 | Inavolisib | — uncovered |
| MYC_TARGETS_V2 | 0.320 | Idelalisib | — uncovered |
| XENOBIOTIC_METABOLISM | 0.300 | Inavolisib | — uncovered |
| FATTY_ACID_METABOLISM | 0.290 | Inavolisib | — uncovered |
| COMPLEMENT | 0.280 | Inavolisib | — uncovered |
| KRAS_SIGNALING_DN | 0.280 | Remibrutinib | — uncovered |
| MYC_TARGETS_V1 | 0.260 | Inavolisib | — uncovered |
| BILE_ACID_METABOLISM | 0.240 | Inavolisib | — uncovered |
| TNFA_SIGNALING_VIA_NFKB | 0.220 | Inavolisib | — uncovered |
| PI3K_AKT_MTOR_SIGNALING | 0.190 | Inavolisib | — uncovered |
| SPERMATOGENESIS | 0.180 | Inavolisib | — uncovered |
| IL2_STAT5_SIGNALING | 0.170 | Idelalisib | — uncovered |